AstraZeneca: NEURO-TTRansform Phase III Results Presented at AAN Showed Eplontersen Demonstrated Consistent and Sustained Improvement in All Measures of Disease and Quality of Life Through 66 Weeks
April 25, 2023
April 25, 2023
WILMINGTON, Delaware, April 25 (TNSres)-- AstraZeneca, a biopharmaceutical company, issued the following news release on April 24, 2023:
Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis' eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group./1
The positive results being presented today in an E . . .
Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis' eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group./1
The positive results being presented today in an E . . .